These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 3565343)

  • 1. Adverse drug reaction reporting.
    Bosco LA
    Am J Gastroenterol; 1987 Apr; 82(4):356-7. PubMed ID: 3565343
    [No Abstract]   [Full Text] [Related]  

  • 2. Postmarketing surveillance.
    Oleen MA
    Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reaction reporting system: developing a well-monitored program.
    Kilarski DJ; Ziegler B; Coarse J; Buchanan C
    Hosp Formul; 1986 Sep; 21(9):949-52. PubMed ID: 10289704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What you should know about FDA-USP Drug Product Problem Reporting Program.
    McGinnis DM
    Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse drug event reporting. Improving the low US reporting rates.
    Edlavitch SA
    Arch Intern Med; 1988 Jul; 148(7):1499-503. PubMed ID: 3382293
    [No Abstract]   [Full Text] [Related]  

  • 6. Adverse-drug-reaction monitoring.
    Faich GA
    N Engl J Med; 1986 Jun; 314(24):1589-92. PubMed ID: 3713757
    [No Abstract]   [Full Text] [Related]  

  • 7. National adverse drug reaction surveillance. 1986.
    Faich GA; Dreis M; Tomita D
    Arch Intern Med; 1988 Apr; 148(4):785-7. PubMed ID: 3355297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug surveillance. Which methods? For which adverse effects? Application to teratogen monitoring].
    Goujard J
    Therapie; 1985; 40(5):287-92. PubMed ID: 4095683
    [No Abstract]   [Full Text] [Related]  

  • 9. [Critical study of methods of postmarketing drug surveillance].
    Gut JP; Auriche M; Spriet-Pourra C; Juillet Y
    Therapie; 1985; 40(5):313-9. PubMed ID: 3913048
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse drug reaction reporting: a working system.
    Michelson PA; Shields K
    Hosp Pharm; 1987 Jul; 22(7):682-4. PubMed ID: 10282685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician knowledge, attitudes, and behavior related to reporting adverse drug events.
    Rogers AS; Israel E; Smith CR; Levine D; McBean AM; Valente C; Faich G
    Arch Intern Med; 1988 Jul; 148(7):1596-600. PubMed ID: 3382304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [How to report side-effects of drugs?].
    Guillaume JC
    Ann Dermatol Venereol; 1986; 113(4):375-6. PubMed ID: 3767239
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1988 Apr; 37(13):197-200. PubMed ID: 2832717
    [No Abstract]   [Full Text] [Related]  

  • 15. Reporting adverse drug therapy results.
    Pa Med; 1990 Jun; 93(6):29. PubMed ID: 2367135
    [No Abstract]   [Full Text] [Related]  

  • 16. Revised ADR report permits internal review of drug experience.
    Jeffrey LP
    Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
    [No Abstract]   [Full Text] [Related]  

  • 17. [Bayesian approach to the imputability of undesirable phenomena to drugs].
    Auriche M
    Therapie; 1985; 40(5):301-6. PubMed ID: 4095686
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccine adverse event reporting: the importance of follow-up.
    Varricchio F
    Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
    [No Abstract]   [Full Text] [Related]  

  • 20. [A network of regional correspondents for studying undesirable effects].
    Haramburu F; Péré JC; Begaud B; Albin H
    Therapie; 1985; 40(5):321-4. PubMed ID: 4095688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.